Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sheila Piva
Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)
Scientific Reports
Multidisciplinary
Related publications
P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Korean Journal of Internal Medicine
Internal Medicine
P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt
Research in Oncology